Praluent Cost in Idaho 2026: Price, Insurance, Medicaid and Compounded Options

What Is Praluent and Why Does It Matter for Idaho Patients

Praluent is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor approved by the FDA for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statins. In ODYSSEY OUTCOMES (N=18,924), alirocumab 75-150 mg every two weeks reduced major adverse cardiovascular events by 15 percent versus placebo (HR 0.85 to 95% CI 0.78-0.93, P<0.001) over a median 2.8 years in post-acute coronary syndrome patients [1]. That is a clinically meaningful absolute risk reduction of 1.6 percentage points.

Idaho has an estimated 3,800 residents living with familial hypercholesterolemia based on the 1-in-313 population prevalence cited by the American Heart Association [2]. Many of them exhaust statin options and face a cost wall with brand-name biologics. Understanding every pricing pathway available in Idaho is not a luxury. It is a clinical necessity.

Brand-Name Praluent: List Price vs. What Idaho Patients Actually Pay

The Wholesale Acquisition Cost (WAC) for Praluent sits at approximately $580 per month in 2026 for either the 75 mg or 150 mg prefilled pen. That number reflects the manufacturer's list price set by Regeneron and Sanofi and does not account for insurer rebates, pharmacy benefit manager (PBM) concessions, or patient assistance programs [3].

Cash-pay patients at Idaho retail pharmacies, including Albertsons, Ridley's, Walmart, and independent chains in Boise, Idaho Falls, and Pocatello, typically see sticker prices close to WAC because PCSK9 inhibitors carry minimal generic competition. GoodRx and NeedyMeds coupons shave a modest amount off the cash price at select pharmacies, but savings rarely exceed 10-15 percent on a branded biologic of this class.

The practical takeaway: a commercially uninsured Idaho resident paying full retail for Praluent would spend roughly $6,960 per year. That figure makes alternative access pathways financially significant.

Idaho Medicaid and PCSK9 Inhibitors: The Coverage Gap

Idaho Medicaid does not currently cover Praluent (alirocumab) for any indication. This places Idaho in a minority of states that have not added PCSK9 inhibitors to their preferred drug list even for high-risk populations such as familial hypercholesterolemia or post-ACS patients.

The American College of Cardiology/American Heart Association 2022 Guideline on the Management of Blood Cholesterol states: "For patients with clinical ASCVD who are at very high risk and on maximally tolerated statin therapy with LDL-C levels remaining 70 mg/dL or higher, it is reasonable to add a PCSK9 inhibitor (Class IIa, Level A)" [4]. Idaho Medicaid's formulary does not reflect this guidance as of mid-2025.

Idaho Health and Welfare reviews its preferred drug list on a quarterly schedule. Advocates and prescribers can submit evidence-based petitions through the Drug Use Review Board process, but approval timelines are unpredictable. Patients currently enrolled in Idaho Medicaid who require alirocumab may qualify for the manufacturer's patient assistance program (see below) since they lack drug coverage for this agent.

Patients on Medicare Part D face a separate but related challenge. Most Part D plans in Idaho place PCSK9 inhibitors on Tier 4 or Tier 5, generating monthly cost-sharing of $200-$400 before the catastrophic coverage phase. The Inflation Reduction Act's $2,000 out-of-pocket cap on Part D beginning in 2025 provides some relief for Medicare beneficiaries who reach that ceiling mid-year.

Private Insurance Coverage for Praluent in Idaho

Commercial insurers operating in Idaho, including Blue Cross of Idaho, Regence BlueShield of Idaho, PacificSource, SelectHealth, and employer self-funded plans administered by national PBMs, generally cover Praluent under specialty pharmacy benefits but impose prior authorization (PA) and step-therapy requirements.

Typical PA criteria include:

• Diagnosis of HeFH (confirmed by clinical criteria or genetic testing) or established ASCVD
• Documentation of maximally tolerated statin therapy for at least 90 days
• LDL-C of 70 mg/dL or higher (some plans use 100 mg/dL) despite statin therapy
• Trial and failure of ezetimibe in addition to statin therapy

Step therapy that requires both a statin trial and an ezetimibe trial adds months to the approval timeline. The ACC/AHA guideline supports ezetimibe as a cost-effective first add-on, so this sequence has clinical logic, but it delays PCSK9 access for patients who may already be statin-intolerant or maximally treated.

Appeals processes in Idaho are governed by state insurance regulations under Title 41 of the Idaho Code. Independent external review is available for denied PA requests and has resulted in overturned denials in documented cases where clinicians submitted ODYSSEY OUTCOMES data and patient-specific risk calculations. A prescribing clinician's detailed letter citing trial data strengthens an appeal substantially.

The Regeneron/Sanofi Praluent Savings Card

For commercially insured patients (not Medicare, not Medicaid), Regeneron and Sanofi offer a copay assistance card that can reduce monthly cost-sharing to as low as $0 per month for eligible Idaho patients [5]. The program is income-independent for commercially insured individuals, which makes it broadly accessible. Eligibility requirements as of 2025:

• US resident with commercial (private) insurance that covers Praluent
• Not enrolled in any federal or state government insurance program (Medicare, Medicaid, TRICARE, or similar)
• Prescription filled at a participating specialty pharmacy

Patients can enroll at myPraluent.com or by calling the Praluent support line. Savings are applied as a point-of-sale discount at the pharmacy, so patients do not need to submit claims manually. The card has an annual maximum benefit; patients should verify the current cap with the manufacturer each year since it is subject to change.

Patients who do not qualify for the savings card because they are uninsured may apply for the Regeneron Patient Assistance Program (PAP) or the Together Rx Access program if their household income falls within program thresholds. These programs can provide Praluent at no cost to qualifying patients.

Compounded Alirocumab in Idaho: Legality and Practical Access

Compounded alirocumab is legally available to Idaho residents through 503A compounding pharmacies licensed in Idaho. 503A pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act and prepare patient-specific compounds based on a valid prescriber order [6]. They are regulated jointly by the FDA and state boards of pharmacy, including the Idaho Board of Pharmacy.

The distinction between 503A and 503B (outsourcing facility) is meaningful here. 503B facilities may produce larger batches for office use but must comply with current Good Manufacturing Practice (cGMP) standards. Most compounded alirocumab for individual patients flows through 503A pharmacies.

A few points Idaho prescribers and patients should understand:

Legal status. Compounding alirocumab is permissible under 503A because alirocumab is not on the FDA's list of drugs that may not be compounded. The FDA's Demonstrably Difficult to Compound list and the list of drugs withdrawn for safety reasons do not include PCSK9 inhibitors as of mid-2025. Prescribers should verify this status has not changed before writing a compound order [7].

Bioequivalence. Compounded alirocumab is not FDA-approved and has not undergone the same bioequivalence or immunogenicity testing as brand Praluent. The active biological sequence may be reproduced, but excipients, formulation, and cold-chain handling differ. Patients and prescribers should weigh this uncertainty against cost savings on an individual basis.

Cost. Compounded alirocumab pricing varies by pharmacy and order size. Some 503A pharmacies offering this compound quote prices substantially below the $580/month brand WAC, with some Idaho-accessible pharmacies listing monthly costs in the range of $150-$250 depending on dose and supply quantity. Telehealth platforms, including those serving Idaho, can connect patients with licensed prescribers who write the compound order for a participating 503A pharmacy.

Cold chain. Like brand Praluent, compounded alirocumab requires refrigeration at 2-8 degrees Celsius. Idaho patients in rural areas should confirm that their pharmacy ships with validated cold-chain packaging and that delivery timelines accommodate local temperatures.

Insurance coverage. Private insurers and Medicaid do not reimburse compounded alirocumab. Patients choosing this route pay out of pocket.

Telehealth Prescribing of Praluent and Compounded Alirocumab in Idaho

Telehealth prescribing of alirocumab (brand or compounded) is legal in Idaho. Idaho Code Title 54 permits prescribing via synchronous audio-video telehealth encounters, and the state's telehealth parity law requires commercial insurers to reimburse telehealth visits at rates comparable to in-person care for covered services [8].

For brand Praluent, a telehealth prescriber can initiate or continue therapy by reviewing lipid panel results, documenting indication (HeFH or established ASCVD), and submitting a PA request electronically to the insurer's specialty pharmacy. Most specialty pharmacies require a clinical summary and recent LDL-C values; these documents transfer easily through secure telehealth platforms.

For compounded alirocumab, the prescribing workflow is simpler: the clinician writes a compound prescription specifying the active ingredient, dose, volume, concentration, and dispensing quantity, then routes it to a licensed 503A pharmacy. No PA is required because insurance is not involved. The patient receives the vials or prefilled syringes by mail.

HealthRX clinicians licensed in Idaho can complete the full prescribing workflow, including lipid panel review, shared decision-making discussion about brand versus compounded options, and prescription routing, within a single telehealth visit. Patients should have a fasting lipid panel drawn within the prior 90 days before the visit where possible.

LDL-C Targets and Monitoring for Idaho Alirocumab Patients

The ACC/AHA guideline defines "very high risk" ASCVD as two or more major ASCVD events or one major event plus multiple high-risk conditions, and recommends an LDL-C target of below 70 mg/dL for this group [4]. For HeFH patients without ASCVD, the target is below 100 mg/dL, with below 70 mg/dL preferred if additional risk factors exist.

Alirocumab lowers LDL-C by 45-61 percent from baseline at the 75 mg dose and by 54-62 percent at the 150 mg dose when added to maximally tolerated statin therapy, based on the ODYSSEY LONG TERM trial (N=2,341) published in the New England Journal of Medicine [9]. A patient on a statin with a baseline LDL-C of 130 mg/dL can expect a post-treatment LDL-C in the 50-75 mg/dL range on the 75 mg dose, which usually meets the guideline target.

Monitoring protocol after initiating alirocumab:

• Fasting lipid panel at 4-8 weeks after initiation to verify response
• If LDL-C remains above target at 8 weeks on 75 mg, uptitrate to 150 mg
• Repeat lipid panel 4-8 weeks after any dose change
• Stable patients can then be monitored every 6-12 months
• Liver function testing is not routinely required (no hepatotoxicity signal in trials)

Injection site reactions occurred in 7.2 percent of alirocumab-treated patients in ODYSSEY OUTCOMES versus 5.1 percent with placebo [1]. They are generally mild and self-limiting. Patients should rotate injection sites between the abdomen, thigh, and upper arm on a regular schedule.

Comparing Alirocumab to Evolocumab (Repatha) for Idaho Patients

Evolocumab (Repatha) is the other FDA-approved PCSK9 inhibitor available in Idaho and carries a similar list price. The FOURIER trial (N=27,564) demonstrated that evolocumab reduced LDL-C by 59 percent and reduced the primary cardiovascular endpoint by 15 percent (HR 0.85, P<0.001) over 2.2 years [10].

The two agents have comparable LDL-C lowering efficacy and a similar cardiovascular outcomes profile. Key practical differences for Idaho patients:

• Dosing schedules differ: alirocumab is available as every-two-week or monthly (300 mg) dosing; evolocumab offers every-two-week (140 mg) or monthly (420 mg) dosing.
• Both are covered under similar PA criteria by Idaho commercial insurers.
• Idaho Medicaid covers neither as of 2025.
• Compounded versions of both exist through 503A pharmacies, with pricing differences by pharmacy.
• Patient preference for a monthly rather than twice-monthly injection schedule may favor the 300 mg alirocumab or 420 mg evolocumab options for adherence.

Prescribers should choose based on patient injection frequency preference, prior authorization formulary positioning at the patient's specific insurer, and shared decision-making about brand versus compounded options.

Step-by-Step: How to Access Praluent or Compounded Alirocumab in Idaho

1. Get a qualifying lipid panel. Order a fasting lipid panel. The result needs to show LDL-C at or above your insurer's threshold (typically 70-100 mg/dL) despite statin therapy, or document statin intolerance with a statin rechallenge trial.

2. Book a telehealth visit. A HealthRX clinician licensed in Idaho reviews your lipid history, cardiovascular risk, and current medications. Bring statin prescription records and any prior PA denial letters.

3. Choose brand or compounded. If you carry commercial insurance and the savings card applies, brand Praluent may cost less out of pocket than you expect. If you are uninsured, on Medicaid, or on Medicare Part D without reaching catastrophic coverage, compounded alirocumab from a licensed 503A pharmacy is often the more accessible route.

4. PA submission (brand) or compound order (compounded). The prescriber submits either the PA package to your specialty pharmacy benefit manager or the compound prescription to a licensed 503A pharmacy. Specialty pharmacy coordination typically takes 5-14 business days for brand; compounded orders from established pharmacies usually ship within 3-7 business days.

5. Receive, store, and inject. Praluent and compounded alirocumab both require refrigerated storage. Remove the pen or syringe 30-40 minutes before injection to allow it to reach room temperature, which reduces injection discomfort.

6. Follow-up lipid panel at 4-8 weeks. This confirms response and guides any dose adjustment. Results can be reviewed in a follow-up telehealth visit.

Idaho-Specific Resources and Contact Points

• Idaho Board of Pharmacy (verifies 503A pharmacy licensure): boardofpharmacy.idaho.gov
• Idaho Department of Health and Welfare (Medicaid drug list inquiries): healthandwelfare.idaho.gov
• Idaho Insurance Department (PA appeals assistance): doi.idaho.gov
• Regeneron/Sanofi Patient Support (savings card and PAP enrollment): myPraluent.com or 1-844-PRALUENT
• NeedyMeds (independent copay and PAP database): needymeds.org